iScience (Nov 2021)

De novo peptide grafting to a self-assembling nanocapsule yields a hepatocyte growth factor receptor agonist

  • Yamato Komatsu,
  • Naohiro Terasaka,
  • Katsuya Sakai,
  • Emiko Mihara,
  • Risa Wakabayashi,
  • Kunio Matsumoto,
  • Donald Hilvert,
  • Junichi Takagi,
  • Hiroaki Suga

Journal volume & issue
Vol. 24, no. 11
p. 103302

Abstract

Read online

Summary: Lasso-grafting (LG) technology is a method for generating de novo biologics (neobiologics) by genetically implanting macrocyclic peptide pharmacophores, which are selected in vitro against a protein of interest, into loops of arbitrary protein scaffolds. In this study, we have generated a neo-capsid that potently binds the hepatocyte growth factor receptor MET by LG of anti-MET peptide pharmacophores into a circularly permuted variant of Aquifex aeolicus lumazine synthase (AaLS), a self-assembling protein nanocapsule. By virtue of displaying multiple-pharmacophores on its surface, the neo-capsid can induce dimerization (or multimerization) of MET, resulting in phosphorylation and endosomal internalization of the MET-capsid complex. This work demonstrates the potential of the LG technology as a synthetic biology approach for generating capsid-based neobiologics capable of activating signaling receptors.

Keywords